Added to YB: 2025-10-28
Pitch date: 2025-10-24
NVO [neutral]
Novo Nordisk A/S
-5.27%
current return
Author Info
Kontra Investment Xchange is trying to build wealth by investing in good companies and letting those investments compound over many years. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 339.00
Price Target
N/A
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
special_situation
Novo Nordisk ($NVO): The Board shake-up is exactly what was needed
NVO (update): Board overhaul w/ Lars Rebien Sørensen (ex-CEO) as Chair, Mikael Dolsten (ex-Pfizer R&D head) joining. Foundation replaced underperforming directors unable to adapt to tough US obesity market & transformation pace. New slate brings pharma, biotech, med-tech expertise needed for GLP-1 defense vs Lilly.
Read full article (3 min)